Price
$26.11+18.63%Social Signal Score
Analyst Ratings
24 analystsRevenue
$156.62M+383.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey A. Tangney
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 880
- Beta
- 1.25
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 20.67
Financials
Revenue
$156.62M+383.0%Net Income
$24.32M+311.9%EBITDA
$44.65M+462.6%Free Cash Flow
$41.92M+440.8%EPS (diluted)
$0.13+300.0%Shares Outstanding (diluted)
191.17M+5.2%Operating Expenses
$99.28MCash & Debt
$687.79MReturn of Capital
$91.63MRevenue by Segment (annual)
$644.86MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $644.86M | $196.05M | $1.05 |
| 2025 | $570.40M | $223.19M | $1.19 |
| 2024 | $475.42M | $147.58M | $0.78 |
| 2023 | $419.05M | $112.82M | $0.58 |
| 2022 | $343.55M | $154.78M | $0.81 |
| 2021 | $206.90M | $50.21M | $0.12 |
| 2020 | $116.39M | $29.74M | $0.06 |
| 2019 | $85.69M | $7.83M | $0.00 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DOCS's reported EPS growth of 127.8% a year over 7 years. Historical EPS growth of 128% reflects a recovery from a low base and won't persist. Capped at 30% as a starting point.
- EPS in 5 years
- $3.89
- Implied price
- $85.63
- Return from $27.93
- 25.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $42.57 — today's price is already 34.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| 20.0% | 8.4% | 12.2% | 15.5% | 18.5% | 21.2% |
| 25.0% | 12.9% | 16.8% | 20.3% | 23.4% | 26.2% |
| 30.0% | 17.4% | 21.5% | 25.1% | 28.4% | 31.3% |
| 35.0% | 21.9% | 26.2% | 29.9% | 33.3% | 36.3% |
| 40.0% | 26.4% | 30.8% | 34.7% | 38.2% | 41.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
96+91.67%Social Signal Score
Mentions (20)
- Newszacks.com·13h ago·Neutral
Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing The latest trading day saw Doximity (DOCS) settling at $28.58, representing a +2.33% change from its previous close.
View source ↗ - Newszacks.com·19h ago·Positive
Reasons to Retain Doximity Stock in Your Portfolio for Now DOCS' rapid clinical AI adoption and strong cash generation support its outlook, but tight pharma budgets and AI costs may limit near-term gains.
View source ↗ - News (Marketaux)gurufocus.com·5d ago·Positive
A Look at Doximity Inc (DOCS) After 6.9% Gain -- GF Value $45.85 vs Price $28.34 On September 30, 2026, Doximity[+247 characters]
View source ↗ - Newsprnewswire.com·5d ago·Negative
Doximity, Inc. (DOCS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit BENSALEM TOWNSHIP, Pa., Sept. 30, 2026 /PRNewswire/ -- The Law Offices of Howard G.
View source ↗ - Newszacks.com·6d ago·Positive
Doximity (DOCS) Gains As Market Dips: What You Should Know In the latest trading session, Doximity (DOCS) closed at $26.52, marking a +1.22% move from the previous day.
View source ↗ - Newsprnewswire.com·6d ago·Neutral
Top Los Angeles Spine Surgeon Dr. Albert Wong Served as Faculty Leader at Advanced Spine Surgery Cadaver Training Courses for SeaSpine and Globus Renowned neurosurgeon Dr. Albert Wong of DOCS Health served as faculty leader at two hands-on cadaver training courses in 2026, teaching minimally invasive
View source ↗ - Newsgurufocus.com·8d ago·Negative
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud LawsuitPR NewswireNEW YORK, Sept. 27, 2026NEW YORK, Sept. 27, 2026 /PRNewswire/ -- Rosen
View source ↗ - Newsbusinesswire.com·13d ago·Neutral
Doximity Named Leading Clinical AI Benchmark in Fireworks' Cross-Industry Index SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform. As part of the launch, Doximity is publishing a new open-source benchmark for measuring clinical-g…
View source ↗ - Newsbusinesswire.com·14d ago·Negative
Securities Fraud Investigation Into Doximity, Inc. (DOCS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON DOXIMITY, INC. (DOCS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY P…
View source ↗ - Newszacks.com·14d ago·Negative
Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing In the closing of the recent trading day, Doximity (DOCS) stood at $26.84, denoting a +2.8% move from the preceding trading day.
View source ↗ - Newsbusinesswire.com·18d ago·Negative
DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $DOCS--DOCS Investors Have Opportunity to Lead Doximity, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newszacks.com·20d ago·Neutral
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note Doximity (DOCS) closed at $25.81 in the latest trading session, marking a -2.2% move from the prior day.
View source ↗ - Newsgurufocus.com·38d ago·Negative
Doximity Inc (DOCS) Shares Surge 4.5% -- What GF Score of 86 Tells Investors On August 28, 2026, Doximity Inc (DOCS) shares rose 4.5% to a current price of $26.73. This performance occurred amidst a 52-week range of $17.15 to $76.51, ind
View source ↗ - Newszacks.com·42d ago·Positive
Reasons to Retain Doximity Stock in Your Portfolio for Now DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.
View source ↗ - Newsfool.com·49d ago·Neutral
Doximity's New CFO Just Filed His First Form 4. Here's What Long-Term Investors Should Know. The disposition involved 15,311 shares valued at about $380,000 based on a weighted average price of $24.80 per share. The transaction reduced the insider's direct holdings by 3% following the underlying vesting event.
View source ↗ - News (Marketaux)finance.yahoo.com·58d ago·Positive
Why Doximity Stock Skyrocketed on Friday Shares of Doximity (NYSE</e[+253 characters]
View source ↗ - Newsfool.com·58d ago·Positive
Why Doximity Stock Skyrocketed on Friday Doximity's AI assistant is earning favorable reviews from independent researchers. Customer usage of Doximity's AI services is soaring.
View source ↗ - Newsseekingalpha.com·58d ago·Neutral
Doximity: I Called The Pop Over A Month Ago, But Now Is The Time To Wait (Rating Downgrade) Doximity delivered strong fiscal Q1 2027 results, validating my prior bullish stance on valuation and AI-driven growth. The stock surged over 30% intraday, reflecting the market's recognition of DOCS's evolving business model and earnings strength. DOCS is transforming physician searches into a new commercial marketplace, leveraging AI Search to monetize real-time physician intent.
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Doximity Q1 Earnings Call Highlights Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.
View source ↗ - 4chan /biz/biz·60d ago·Neutral
DOCS up 80% AH
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.34 per share
Typical surprise +18.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.29 vs $0.30miss
- Wed, May 13$0.26 vs $0.28miss
- Thu, Feb 5$0.46 vs $0.44beat
- Thu, Nov 6$0.45 vs $0.38beat
- Thu, Aug 7$0.36 vs $0.30beat
- Thu, May 15$0.38 vs $0.27beat
Estimates and results for DOCS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DOCS officers and directors.
- Bought
- —
- Sold
- $1.2m
0 trades
15 trades
- Yang Watkin Phoebe L.sold
- Sitaram Siddharthsold
- Wampler Kira Scherersold
- Wampler Kira Scherersold
- Sitaram Siddharthsold
- Cabral Timothy Ssold
- Sitaram Siddharthsold
- Sitaram Siddharthsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Jonathan Jacksonhouse · IL01 · disclosed Dec 8, 2025 (32d later)Sell$15,001 - $50,000
- Jonathan Jacksonhouse · IL01 · disclosed Sep 24, 2025 (30d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.